(Q38125501)

29 August 2017

title

Recent advances revolutionize treatment of metastatic prostate cancer (English)

1 reference

29 August 2017

1 reference

Ravi A Madan

1

1 reference

29 August 2017

Philip M Arlen

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

9

1 reference

29 August 2017

issue

8

1 reference

29 August 2017

page(s)

1133-1144

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

29 August 2017

cites work

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

21 January 2018

1 reference

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2012

1 reference

Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

21 January 2018

1 reference

Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy

21 January 2018

1 reference

Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails

21 January 2018

1 reference

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

21 January 2018

1 reference

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

21 January 2018

1 reference

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)

21 January 2018

1 reference

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

21 January 2018

1 reference

ARN-509: a novel antiandrogen for prostate cancer treatment

21 January 2018

1 reference

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

21 January 2018

1 reference

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

21 January 2018

1 reference

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer

21 January 2018

1 reference

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

21 January 2018

1 reference

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression

21 January 2018

1 reference

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

21 January 2018

1 reference

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

21 January 2018

1 reference

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

21 January 2018

1 reference

Clinical evaluation of TRICOM vector therapeutic cancer vaccines

21 January 2018

1 reference

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

21 January 2018

1 reference

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

c-met proto-oncogene expression in benign and malignant human prostate tissues

21 January 2018

1 reference

Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting

21 January 2018

1 reference

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

21 January 2018

1 reference

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

21 January 2018

1 reference

S100A9 interaction with TLR4 promotes tumor growth

21 January 2018

1 reference

The role of myeloid cells in the promotion of tumour angiogenesis

21 January 2018

1 reference

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

21 January 2018

1 reference

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.13.65

1 reference

29 August 2017

1 reference